Research Article

Department of Respiratory Medicine, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua City, Zhejiang Province, 321000, China

Search for more papers by this author

Xu Yang

https://orcid.org/0000-0002-8901-9108

Department of Respiratory Medicine, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua City, Zhejiang Province, 321000, China

Search for more papers by this author

Shasha Gao

https://orcid.org/0000-0002-5682-3327

Department of Respiratory Medicine, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua City, Zhejiang Province, 321000, China

Search for more papers by this author

Minya Wen

https://orcid.org/0000-0002-0447-0582

Department of Laboratory, Jinhua Wenrong Hospital, Jinhua City, Zhejiang Province, 322118, China

Search for more papers by this author

Qiong Yu

*Author for correspondence: Tel.: +86 138 6798 3231;

E-mail Address: qiongyuass@163.com

https://orcid.org/0000-0001-7583-9984

Department of Respiratory Medicine, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua City, Zhejiang Province, 321000, China

Search for more papers by this author

Published Online:13 Feb 2023https://doi.org/10.2217/pgs-2022-0121

View article

Abstract

Aim: To investigate the influence of DDX11-AS1 on paclitaxel (PTX) resistance in lung adenocarcinoma (LUAD). Methods: LncRNA expression and functional enrichment analyses were processed via bioinformatics methods. DDX11-AS1 expression was detected via quantitative real-time PCR. Cell counting kit-8, colony formation, flow cytometry and comet assays were manipulated to measure cell proliferation, apoptosis, cell cycle and DNA damage repair, respectively. Western blot was used to assess DNA damage-related protein expression. Results:DDX11-AS1 was in a high expression status in LUAD, and could promote LUAD cell proliferation and PTX resistance, while suppressing cell apoptosis. DNA damage repairing ability was also modulated by the change of DDX11-AS1 expression. Conclusion: LncRNA DDX11-AS1 promotes DNA damage repair to enhance PTX resistance in LUAD.

Keywords:

References

1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
MedlineGoogle Scholar
2. Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 9(2), 117 (2018).
MedlineGoogle Scholar
3. Inamura K. Clinicopathological characteristics and mutations driving development of early lung adenocarcinoma: tumor initiation and progression. Int. J. Mol. Sci. 19(4), 1259 (2018).
MedlineGoogle Scholar
4. Abu Samaan TM, Samec M, Liskova A, Kubatka P, Busselberg D. Paclitaxel's mechanistic and clinical effects on breast cancer. Biomolecules 9(12), 789 ( 2019).
MedlineGoogle Scholar
5. Kellokumpu-Lehtinen P, Tuunanen T, Asola R et al. Weekly paclitaxel – an effective treatment for advanced breast cancer. Anticancer Res. 33(6), 2623–2627 (2013).
Medline CASGoogle Scholar
6. Van Vuuren RJ, Visagie MH, Theron AE, Joubert AM. Antimitotic drugs in the treatment of cancer. Cancer Chemother. Pharmacol. 76(6), 1101–1112 (2015).
Medline CASGoogle Scholar
7. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell 25(18), 2677–2681 (2014).
MedlineGoogle Scholar
8. Bhat SA, Ahmad SM, Mumtaz PT et al. Long non-coding RNAs: mechanism of action and functional utility. Noncoding RNA Res. 1(1), 43–50 (2016).
MedlineGoogle Scholar
9. Huarte M. The emerging role of lncRNAs in cancer. Nat. Med. 21(11), 1253–1261 (2015).
Medline CASGoogle Scholar
10. Chen D, Chen J, Gao J et al. LncRNA DDX11-AS1 promotes bladder cancer occurrence via protecting LAMB3 from downregulation by sponging miR-2355-5p. Cancer Biother. Radiopharm. 35(5), 319–328 (2020).
Medline CASGoogle Scholar
11. Ren Z, Liu X, Si Y, Yang D. Long non-coding RNA DDX11-AS1 facilitates gastric cancer progression by regulating miR-873-5p/SPC18 axis. Artif. Cells Nanomed. Biotechnol. 48(1), 572–583 (2020).
Medline CASGoogle Scholar
12. Tian JB, Cao L, Dong GL. Long noncoding RNA DDX11-AS1 induced by YY1 accelerates colorectal cancer progression through targeting miR-873/CLDN7 axis. Eur. Rev. Med. Pharmacol. Sci. 23(13), 5714–5729 (2019).
MedlineGoogle Scholar
13. Li Y, Zhuang W, Huang M, Li X. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 514(4), 1051–1057 (2019).
Medline CASGoogle Scholar
14. Feng X, Yang S, Zhou S, Deng S, Xie Y. Long non-coding RNA DDX11-AS1 promotes non-small cell lung cancer development via regulating PI3K/AKT signalling. Clin. Exp. Pharmacol. Physiol. 47(9), 1622–1631 (2020).
Medline CASGoogle Scholar
15. Song W, Qian Y, Zhang MH et al. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer. Eur. Rev. Med. Pharmacol. Sci. 24(6), 3049–3061 (2020).
Medline CASGoogle Scholar
16. Zhang S, Jiang H, Xu Z et al. The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition. Am. J. Cancer Res. 9(10), 2233–2248 (2019).
Medline CASGoogle Scholar
17. Liang M, Zhu B, Wang M, Jin J. Knockdown of long non-coding RNA DDX11-AS1 inhibits the proliferation, migration and paclitaxel resistance of breast cancer cells by upregulating microRNA-497 expression. Mol. Med. Rep. 25(4), 123 (2022).
Medline CASGoogle Scholar
18. Robinson MD, Mccarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1), 139–140 (2010).
Medline CASGoogle Scholar
19. Zhao XG, Hu JY, Tang J et al. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 10(7), 479 (2019).
MedlineGoogle Scholar
20. Guo C, Wang H, Jiang H, Qiao L, Wang X. Circ_0011292 enhances paclitaxel resistance in non-small cell lung cancer by regulating miR-379-5p/TRIM65 axis. Cancer Biother. Radiopharm. 37(2), 84–95 (2022).
Medline CASGoogle Scholar
21. Sanches JGP, Song B, Zhang Q et al. The role of KDM2B and EZH2 in regulating the stemness in colorectal cancer through the PI3K/AKT pathway. Front. Oncol. 11, 637298 (2021).
MedlineGoogle Scholar
22. Liu R, Shen L, Lin C et al. MiR-1587 regulates DNA damage repair and the radiosensitivity of CRC cells via targeting LIG4. Dose Response 18(2), 1559325820936906 (2020).
Google Scholar
23. Khandekar MJ, Banks AS, Laznik-Bogoslavski D et al. Noncanonical agonist PPARgamma ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. Proc. Natl Acad. Sci. USA 115(3), 561–566 (2018).
Medline CASGoogle Scholar
24. Spella M, Stathopoulos GT. Immune resistance in lung adenocarcinoma. Cancers (Basel) 13(3), 384 (2021).
Medline CASGoogle Scholar
25. Mao Y, Xu R. Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma. Biomed. Pharmacother. 123, 109771 (2020).
Medline CASGoogle Scholar
26. Ding G, Zeng Y, Yang D et al. Silenced lncRNA DDX11-AS1 or up-regulated microRNA-34a-3p inhibits malignant phenotypes of hepatocellular carcinoma cells via suppression of TRAF5. Cancer Cell Int. 21(1), 179 (2021).
Medline CASGoogle Scholar
27. Wan T, Zheng J, Yao R, Yang S, Zheng W, Zhou P. LncRNA DDX11-AS1 accelerates hepatocellular carcinoma progression via the miR-195-5p/MACC1 pathway. Ann. Hepatol. 20, 100258 (2021).
Medline CASGoogle Scholar
28. Xu M, Zhao X, Zhao S et al. Landscape analysis of lncRNAs shows that DDX11-AS1 promotes cell-cycle progression in liver cancer through the PARP1/p53 axis. Cancer Lett. 520, 282–294 (2021).
Medline CASGoogle Scholar
29. Wu C, Wang Z, Tian X, Wang J, Zhang Y, Wu B. Long non-coding RNA DDX11-AS1 promotes esophageal carcinoma cell proliferation and migration through regulating the miR-514b-3p/RBX1 axis. Bioengineered 12(1), 3772–3786 (2021).
Medline CASGoogle Scholar
30. Xiang Z, Lv Q, Zhang Y et al. Long non-coding RNA DDX11-AS1 promotes the proliferation and migration of glioma cells by combining with HNRNPC. Mol. Ther. Nucleic Acids 28, 601–612 (2022).
Medline CASGoogle Scholar
31. Kotake Y, Goto T, Naemura M, Inoue Y, Okamoto H, Tahara K. Long noncoding RNA PANDA positively regulates proliferation of osteosarcoma cells. Anticancer Res. 37(1), 81–85 (2017).
MedlineGoogle Scholar
32. Sharma V, Khurana S, Kubben N et al. A BRCA1-interacting lncRNA regulates homologous recombination. EMBO Rep. 16(11), 1520–1534 (2015).
Medline CASGoogle Scholar
33. Wan G, Hu X, Liu Y et al. A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J. 32(21), 2833–2847 (2013).
Medline CASGoogle Scholar
34. Ju ZS, Sun B, Bao D, Zhang XF. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression. Eur. Rev. Med. Pharmacol. Sci. 24(18), 9465–9472 (2020).
MedlineGoogle Scholar
35. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ. Mol. Mutagen. 58(5), 235–263 (2017).
Medline CASGoogle Scholar
36. Hopkins JL, Lan L, Zou L. DNA repair defects in cancer and therapeutic opportunities. Genes Dev. 36(5-6), 278–293 (2022).
Medline CASGoogle Scholar

Vol. 24, No. 3

Metrics

Downloaded 74 times

History

Received 2 September 2022

Accepted 18 January 2023

Published online 13 February 2023

Published in print February 2023

Information

Keywords

Author contributions

J Liu conceived and designed the study. X Yang, S Gao and M Wen performed the experiments. Q Yu wrote the paper. J Liu, X Yang, S Gao and M Wen reviewed and edited the manuscript. All authors read and approved the manuscript.

Financial & competing interests disclosure

This study was supported in part by grants from the Public Welfare Fund of Jinhua Science and Technology Bureau of Zhejiang Province (grant no. 2020-4-076). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Consent for publication

All authors consent to submit the manuscript for publication.

Availability of date & materials

The date and materials in the current study are available from the corresponding author on reasonable request.

PDF download

DDX11-AS1 modulates DNA damage repair to enhance paclitaxel resistance of lung adenocarcinoma cells

Abstract

References